Terms: = Bone cancer AND STAT5B, STAT5, 6777, ENSG00000173757, P51692 AND Treatment
58 results:
1. Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis.
Sasine JP; Kozlova NY; Valicente L; Dukov J; Tran DH; Himburg HA; Kumar S; Khorsandi S; Chan A; Grohe S; Li M; Kan J; Sehl ME; Schiller GJ; Reinhardt B; Singh BK; Ho R; Yue P; Pasquale EB; Chute JP
Cancer Res; 2024 Mar; 84(6):919-934. PubMed ID: 38231476
[TBL] [Abstract] [Full Text] [Related]
2. A newly identified 45-kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance.
Gorantla SP; Mueller TA; Albers-Leischner C; Rudelius M; von Bubnoff N; Duyster J
Mol Oncol; 2024 Feb; 18(2):415-430. PubMed ID: 38104968
[TBL] [Abstract] [Full Text] [Related]
3. JAK inhibitor treatment for inborn errors of JAK/STAT signaling: An ESID/EBMT-IEWP retrospective study.
Fischer M; Olbrich P; Hadjadj J; Aumann V; Bakhtiar S; Barlogis V; von Bismarck P; Bloomfield M; Booth C; Buddingh EP; Cagdas D; Castelle M; Chan AY; Chandrakasan S; Chetty K; Cougoul P; Crickx E; Dara J; Deyà-Martínez A; Farmand S; Formankova R; Gennery AR; Gonzalez-Granado LI; Hagin D; Hanitsch LG; Hanzlikovà J; Hauck F; Ivorra-Cortés J; Kisand K; Kiykim A; Körholz J; Leahy TR; van Montfrans J; Nademi Z; Nelken B; Parikh S; Plado S; Ramakers J; Redlich A; Rieux-Laucat F; Rivière JG; Rodina Y; Júnior PR; Salou S; Schuetz C; Shcherbina A; Slatter MA; Touzot F; Unal E; Lankester AC; Burns S; Seppänen MRJ; Neth O; Albert MH; Ehl S; Neven B; Speckmann C
J Allergy Clin Immunol; 2024 Jan; 153(1):275-286.e18. PubMed ID: 37935260
[TBL] [Abstract] [Full Text] [Related]
4. stat5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia.
Huang ZW; Zhang XN; Zhang L; Liu LL; Zhang JW; Sun YX; Xu JQ; Liu Q; Long ZJ
Signal Transduct Target Ther; 2023 Sep; 8(1):391. PubMed ID: 37777506
[TBL] [Abstract] [Full Text] [Related]
5. Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers.
Zhang X; Guo H; Chen J; Xu C; Wang L; Ke Y; Gao Y; Zhang B; Zhu J
Cancer Lett; 2023 Sep; 572():216355. PubMed ID: 37597651
[TBL] [Abstract] [Full Text] [Related]
6. IL-7: Comprehensive review.
Winer H; Rodrigues GOL; Hixon JA; Aiello FB; Hsu TC; Wachter BT; Li W; Durum SK
Cytokine; 2022 Dec; 160():156049. PubMed ID: 36201890
[TBL] [Abstract] [Full Text] [Related]
7. FAT10 stimulates the development of osteosarcoma by regulating the JAK/STAT signaling pathway.
Shi F; Li L; Cheng Y
J BUON; 2021; 26(5):2090-2096. PubMed ID: 34761621
[TBL] [Abstract] [Full Text] [Related]
8. The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML.
Charlet A; Kappenstein M; Keye P; Kläsener K; Endres C; Poggio T; Gorantla SP; Kreutmair S; Sänger J; Illert AL; Miething C; Reth M; Duyster J; Rummelt C; von Bubnoff N
Leukemia; 2022 Mar; 36(3):701-711. PubMed ID: 34750506
[TBL] [Abstract] [Full Text] [Related]
9. Aberrantly low STAT3 and stat5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia.
Narayanan P; Man TK; Gerbing RB; Ries R; Stevens AM; Wang YC; Long X; Gamis AS; Cooper T; Meshinchi S; Alonzo TA; Redell MS
Clin Transl Oncol; 2021 Oct; 23(10):2141-2154. PubMed ID: 33948920
[TBL] [Abstract] [Full Text] [Related]
10. Ruxolitinib for the treatment of Chronic GVHD and Overlap Syndrome in Children and Young Adults.
Wang YM; Teusink-Cross A; Elborai Y; Krupski MC; Nelson AS; Grimley MS; Flannery A; Mehta PA; Bleesing JJ; Chandra S; Kumar AR; Myers KC; Davies SM; Khandelwal P
Transplantation; 2022 Feb; 106(2):412-419. PubMed ID: 33795598
[TBL] [Abstract] [Full Text] [Related]
11. The delta isoform of phosphatidylinositol-3-kinase predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib.
Villaume MT; Arrate MP; Ramsey HE; Sunthankar KI; Jenkins MT; Moyo TK; Smith BN; Fischer MA; Childress MA; Gorska AE; Ferrell PB; Savona MR
Exp Hematol; 2021 May; 97():57-65.e5. PubMed ID: 33617893
[TBL] [Abstract] [Full Text] [Related]
12. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
Talpaz M; Kiladjian JJ
Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
[TBL] [Abstract] [Full Text] [Related]
13. Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms.
Patel AB; Pomicter AD; Yan D; Eiring AM; Antelope O; Schumacher JA; Kelley TW; Tantravahi SK; Kovacsovics TJ; Shami PJ; O'Hare T; Deininger MW
Leukemia; 2020 Nov; 34(11):2981-2991. PubMed ID: 32409689
[TBL] [Abstract] [Full Text] [Related]
14. A lipid-soluble extract of Pinellia pedatisecta Schott orchestrates intratumoral dendritic cell-driven immune activation through SOCS1 signaling in cervical cancer.
Wang Y; Lu C; Huang H; Yao S; Xu C; Ye Y; Gui S; Li G
J Ethnopharmacol; 2021 Mar; 267():112837. PubMed ID: 32276009
[TBL] [Abstract] [Full Text] [Related]
15. Suppressing stat5 signaling affects osteosarcoma growth and stemness.
Subramaniam D; Angulo P; Ponnurangam S; Dandawate P; Ramamoorthy P; Srinivasan P; Iwakuma T; Weir SJ; Chastain K; Anant S
Cell Death Dis; 2020 Feb; 11(2):149. PubMed ID: 32094348
[TBL] [Abstract] [Full Text] [Related]
16. Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms.
Sapre M; Tremblay D; Wilck E; James A; Leiter A; Coltoff A; Koshy AG; Kremyanskaya M; Hoffman R; Mascarenhas JO; Gallagher EJ
Sci Rep; 2019 Nov; 9(1):16609. PubMed ID: 31719581
[TBL] [Abstract] [Full Text] [Related]
17. LCP1 triggers mTORC2/AKT activity and is pharmacologically targeted by enzastaurin in hypereosinophilia.
Ma G; Gezer D; Herrmann O; Feldberg K; Schemionek M; Jawhar M; Reiter A; Brümmendorf TH; Koschmieder S; Chatain N
Mol Carcinog; 2020 Jan; 59(1):87-103. PubMed ID: 31691359
[TBL] [Abstract] [Full Text] [Related]
18. Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of stat5-CD71 pathway.
Wang X; Yang J; Guo G; Feng R; Chen K; Liao Y; Zhang L; Sun L; Huang S; Chen JL
Mol Cancer; 2019 Apr; 18(1):84. PubMed ID: 30961617
[TBL] [Abstract] [Full Text] [Related]
19. Decreased expression of stat5A predicts poor prognosis in osteosarcoma.
Guo Z; Tang Y; Fu Y; Wang J
Pathol Res Pract; 2019 Mar; 215(3):519-524. PubMed ID: 30638860
[TBL] [Abstract] [Full Text] [Related]
20. Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms.
Cortés AA; Diaz RA; Hernández-Campo P; Gorrochategui J; Primo D; Robles A; Morales ML; Ballesteros J; Rapado I; Gallardo M; Linares M; Martínez-López J
Haematologica; 2019 May; 104(5):937-946. PubMed ID: 30545926
[TBL] [Abstract] [Full Text] [Related]
[Next]
